Your session is about to expire
← Back to Search
FDG-PET and Circulating HPV for Cervical Cancer
N/A
Waitlist Available
Led By Eric Leung, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre treatment and within the first 3 months post treatment
Awards & highlights
Study Summary
This trial is testing whether or not plasma HPV DNA can help predict progression or recurrence of cervical cancer after treatment. 20 patients with locally advanced cervical cancer will be recruited.
Eligible Conditions
- Cervical Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ pre treatment and within the first 3 months post treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre treatment and within the first 3 months post treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from baseline in plasma HPV DNA to 3 months.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Cervical Swab, PET-CT and plasma HPVExperimental Treatment3 Interventions
Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET-CT
2014
N/A
~570
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,550,538 Total Patients Enrolled
Princess Margaret Hospital, CanadaOTHER
119 Previous Clinical Trials
38,975 Total Patients Enrolled
Eric Leung, MDPrincipal InvestigatorSunnybrook Research Institute
3 Previous Clinical Trials
510 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are expected to live for at least 3 more months.You are unable to lie flat on your back for radiation or a type of scan called 18FDG PET-CT.You cannot have radiotherapy because of a medical condition like severe Crohn's disease.You have had cancer before, except for non-melanoma skin cancer or cancer that was treated and has been gone for at least 5 years.You have a medical condition that makes it unsafe for you to receive chemotherapy, such as irreversible kidney failure.
Research Study Groups:
This trial has the following groups:- Group 1: Cervical Swab, PET-CT and plasma HPV
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Have recruitment efforts for this experiment begun yet?
"The study's page on clinicaltrials.gov states that it is no longer in the process of patient recruitment. Initially posted November 23rd 2016, this medical trial was last updated September 20th 2021 and has since ceased recruiting. However, 398 other trials are still looking for potential participants at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger